Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

ABSTRACT:

Objective

Dysregulation of innate and adaptive immune responses contributes to the pathogenesis of systemic lupus erythematosus (SLE) and its associated premature vascular damage. No drug to date targets both systemic inflammatory disease and the cardiovascular complications of SLE. Tofacitinib is a JAK inhibitor that blocks signaling downstream of multiple cytokines implicated in lupus pathogenesis. While clinical trials have shown that tofacitinib exhibits significant clinical efficacy in various autoimmune diseases, its role in SLE and the associated vascular pathology remains to be characterized.

Methods

MRL/lpr lupus-prone mice were administered tofacitinib or vehicle by gavage for 6 weeks (therapeutic arm) or 8 weeks (preventive arm). Nephritis, skin inflammation, seru

SUBMITTER: Furumoto Y 

PROVIDER: S-EPMC5195893 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature